Therapeutic Indications

Ceritinib is indicated for:

First-line treatment of anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC)

Irrespective of gender only Adults (18 years old or older)

Ceritinib as monotherapy is indicated for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).

Ceritinib as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Oral - 450 mg once daily

Contraindications

Active ingredient Ceritinib is contraindicated in the following cases: